Cite
HARVARD Citation
Naumann, R. et al. (n.d.). 138 Phase 1 dose-escalation study of STRO-002, an anti-folate receptor alpha (FRα) antibody drug conjugate (ADC), in patients with advanced platinum-resistant/refractory epithelial ovarian cancer (OC). International journal of gynecological cancer. p. A61. [Online].